Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2026)
Cullinan Therapeutics (CGEM) posted quarterly Cash from Operations of 46045000.0 for Q1 2026, down 6.7% year-over-year from 49349856.58 in Q1 2025, and down 20.82% quarter-over-quarter from 38109000.0 in Q4 2025.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Cash from Operations (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 46045000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 6.7% year-over-year to 46045000.0; the TTM figure through Mar 2026 stood at 178640000.0 (down 18.93% YoY), while the FY2025 annual figure was 175750000.0, down 20.95% from the prior year.
- Cash from Operations for Q1 2026 stood at 46045000.0, down from 38109000.0 in the prior quarter.
- The five-year high for Cash from Operations was 18131000.0 in Q4 2023, with the low at 57609000.0 in Q2 2025.
- The 5-year median for Cash from Operations is 36626000.0 (2024), against an average of 36943352.94.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations tumbled 1346.07% in 2022, then jumped 37.19% in 2023.
- Cullinan Therapeutics' Cash from Operations stood at 24983000.0 in 2022, then rose by 27.43% to 18131000.0 in 2023, then plunged by 102.01% to 36626000.0 in 2024, then decreased by 4.05% to 38109000.0 in 2025, then slipped by 20.82% to 46045000.0 in 2026.
- Business Quant data shows CGEM's Cash from Operations at 46045000.0 in Q1 2026, 38109000.0 in Q4 2025, and 36877000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | -38.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -38.22 Mn |
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -38.11 Mn |
| Sep 30, 2025 | -36.88 Mn |
| Jun 30, 2025 | -57.61 Mn |
| Mar 31, 2025 | -43.16 Mn |
| Dec 31, 2024 | -36.63 Mn |
| Sep 30, 2024 | -34.14 Mn |
| Jun 30, 2024 | -36.29 Mn |
| Mar 31, 2024 | -38.25 Mn |
| Dec 31, 2023 | -18.13 Mn |
| Sep 30, 2023 | -34.14 Mn |
| Jun 30, 2023 | -31.01 Mn |
| Mar 31, 2023 | -51.00 Mn |
| Dec 31, 2022 | -24.98 Mn |
| Sep 30, 2022 | -54.35 Mn |
| Jun 30, 2022 | -25.42 Mn |
| Mar 31, 2022 | -21.91 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -10.55 Mn |